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Platelet-rich plasma releasate differently 
stimulates cellular commitment toward 
the chondrogenic lineage according to 
concentration
Ronaldo JFC do Amaral1,2, Amos Matsiko3,4,5, Marcel RP Tomazette6, 
Wanessa KR Rocha7, Eric Cordeiro-Spinetti6, Tanya J Levingstone3,4,5, 
Marcos Farina1, Fergal J O’Brien3,4,5, Marcia C El-Cheikh1 and 
Alex Balduino2,6
Abstract
Platelet-rich plasma has been used to treat articular cartilage defects, with the expectations of anabolic and anti-
inflammatory effects. However, its role on cellular chondrogenic or fibrogenic commitment is still a controversy. 
Herein, the role of platelet-rich plasma releasate, the product obtained following platelet-rich plasma activation, on 
cellular commitment toward the chondrogenic lineage was evaluated in vitro. Human nasoseptal chondrogenic cells 
and human bone marrow mesenchymal stromal cells were used as cell types already committed to the chondrogenic 
lineage and undifferentiated cells, respectively, as different concentrations of platelet-rich plasma releasate were tested in 
comparison to commonly used fetal bovine serum. Low concentration of platelet-rich plasma releasate (2.5%) presented 
similar effects on cellular growth compared to 10% fetal bovine serum, for both cell types. In a three-dimensional 
culture system, platelet-rich plasma releasate alone did not induce full nasoseptal chondrogenic cells cartilage-like pellet 
formation. Nonetheless, platelet-rich plasma releasate played a significant role on cell commitment as high-passage 
nasoseptal chondrogenic cells only originated cartilage-like pellets when expanded in the presence of platelet-rich plasma 
releasate rather than fetal bovine serum. Histological analyses and measurements of pellet area demonstrated that even 
low concentrations of platelet-rich plasma releasate were enough to prevent nasoseptal chondrogenic cells from losing 
their chondrogenic potential due to in vitro expansion thereby promoting their recommitment. Low concentration 
of platelet-rich plasma releasate supplemented in chondrogenic medium also increased the chondrogenic potential of 
mesenchymal stromal cells seeded on collagen-hyaluronic acid scaffolds, as observed by an increase in chondrogenic-
related gene expression, sulfated glycosaminoglycan production, and compressive modulus following in vitro culture. 
On the contrary, higher concentration of platelet-rich plasma releasate (10%) hampered some of these features. In 
conclusion, platelet-rich plasma releasate was able to prevent cellular chondrogenic capacity loss, inducing regain of 
their phenotype, and modulate cell commitment. Our data support the hypothesis of platelet-rich plasma chondrogenic 
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potential, allowing fetal bovine serum substitution for platelet-rich plasma releasate at specific concentrations in culture 
medium when chondrogenic commitment is desired on specific cell types and moments of culture.
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Introduction
Articular cartilage is an avascular, alymphatic, aneural, and 
hypocellular tissue. Such characteristics contribute to its 
low self-regenerative capacity.1 Chondrocytes produce car-
tilage extracellular matrix (ECM) and, under physiological 
conditions, these cells efficiently contribute to tissue turno-
ver. Nonetheless, under pathological conditions, such as 
large chondral defects, chondrocytes are unable to prolifer-
ate, migrate, and synthesize de novo cartilage ECM in 
order to promote tissue regeneration.2 Current treatments 
are based on palliative strategies such as analgesics and 
nonsteroidal anti-inflammatory drugs administration; non-
reparative such as debridement, chondral shaving, and knee 
joint lavage; and reparative such as microfracture, and sub-
chondral drilling, which are based on stimulation of prolif-
eration and differentiation of subchondral bone marrow 
progenitor cells resulting in fibrous tissue formation.3
Cell-based therapies emerged as a promising clinical 
intervention in cartilage defect repair. Autologous chondro-
cyte implantation (ACI) is one such approach whereby 
autologous chondrocytes are isolated from a healthy non-
weight bearing region of the joint, expanded in vitro, and 
subsequently implanted into the lesion.4,5 Second- and 
third-generation ACI approaches, which rely on the use of 
collagen membranes and porous scaffolds, respectively, 
have demonstrated more advanced regenerative potential.6 
However, the drawbacks associated with the use of autolo-
gous chondrocytes still prevail, including donor site mor-
bidity and limited tissue source. Moreover, fibrous tissue 
formation after cell implantation is associated with a major 
drawback, chondrocyte dedifferentiation during in vitro 
expansion.7,8 Although the use of recombinant factors such 
as TGF-β1, FGF-2, PDGF-BB, and IGF-1 can effectively 
promote chondrocyte redifferentiation in vitro,9–11 the pro-
duction of such therapeutics represents a high cost proce-
dure. These and other factors such as TGF-β2,12 HGF,13 and 
BMP-2,14 which have also been shown to stimulate chon-
drogenesis in vitro, are present in platelet alpha granules 
and are released upon platelet activation.15 These observa-
tions indicate that platelet-rich plasma releasate (PRPr) 
might be an interesting source of chondrogenic factors.
Platelets can be easily and cost-effectively separated 
from other blood components, concentrated in plasma to 
form platelet-rich plasma (PRP), and when activated with 
exogenous thrombin or calcium can trigger endogenous 
thrombin formation and importantly the release of high 
concentrations of different cytokines and growth factors.16 
It has been recently reviewed that although preclinical and 
clinical reports generally show promising histological and 
clinical results when PRP is used in vivo, there is still 
inconclusive scientific evidence to support its use for the 
repair of cartilage defects.17–19
Besides articular chondrocytes, many cell types have 
been identified as promising for future cell therapy proto-
cols to treat cartilage defects.20,21 Some progenitors are 
found in an undifferentiated state, as mesenchymal stromal 
cells (MSCs), and others are already committed to the chon-
drogenic lineage, as human nasoseptal chondrogenic cells 
(NCCs). MSCs are characterized mostly by their multipo-
tency and ability to originate colonies of fibroblast-like cells 
in vitro.22,23 These cells can be isolated from a range of dif-
ferent tissue types such as bone marrow, adipose tissue, and 
synovia.24 Although MSCs could be used therapeutically for 
cartilage repair,3 the addition of growth factors is tradition-
ally required to promote their differentiation toward the 
chondrogenic lineage in vitro, in particular, factors from the 
TGF-β superfamily.25 Human NCCs, on the other hand, 
residing on the surface of the nasoseptal hyaline cartilage, 
can be easily harvested and cultured, and have been demon-
strated to have an intrinsic chondrogenic commitment. In 
the absence of growth factors, NCCs up to the third passage 
are able to synthesize a hyaline-like cartilage in a pellet cul-
ture system.26 The chondrogenic capacity of progenitor cells 
from the nasal septum is also being investigated by other 
groups.27–29 Using two different cell culture models, NCCs 
and MSCs, the aim of this study was to investigate the effect 
of PRPr on cell proliferation and commitment (or loss of it) 
toward the chondrogenic lineage in vitro.
Materials and methods
PRP preparation
Two methods for PRPr preparation were used. The first 
protocol was based on using platelet concentrate bags, 
which would not be used in clinics, following approval 
from the Research Ethics Committee of the Instituto 
Estadual de Hematologia Arthur de Siqueira Cavalcanti 
(201042).
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Platelet concentrate (n = 7) was transferred to 50 mL 
Falcon tubes (Corning Incorporated, Corning, NY, USA). 
Platelet counting was performed by the Brilliant Blue 
Cresyl (Sigma Chemical Co., St Louis, MO, USA) stain-
ing and observation under hemocytometer. For inducing 
platelet activation, 1 M CaCl2 solution was added to tubes, 
in a proportion of 1:50, reaching a final concentration of 
20 mM CaCl2. Tubes were maintained at 37°C for 1 h, after 
that a clot was formed. Tubes were then incubated over-
night at 4°C for clot retraction. Finally, tubes were centri-
fuged at 3000 r/min for 5 min (Centrifuge 5810 R; 
Eppendorf). The final supernatant (PRPr) was frozen at 
−20°C for future in vitro analysis.
The second protocol was based on immediate use of 
blood collection, following consent and under the Royal 
College of Surgeons in Ireland (RCSI) Ethics Committee 
approval (REC676), as previously described, with minor 
modifications.30
Briefly, 54 mL peripheral blood from six donors (n = 6) 
was collected into 60-mL syringe filled with 6 mL of 3.2% 
sodium citrate solution (Sigma). Blood was transferred to 
50-mL tube (Corning) and centrifuged at 300g for 5 min. 
The buffy coat and the red blood cell layer remained intact, 
while the upper fraction was transferred to new tubes, 
which was further centrifuged at 700g for 17 min. After 
second centrifugation step, platelets pellet was resuspended 
with the supernatant (platelet-poor plasma), forming the 
inactivated PRP. Platelets were counted using a hematology 
analyzer (Sysmex, Kobe, Japan). The platelet activation 
was achieved as previously described for protocol 1.
Scaffold fabrication
Collagen-hyaluronic acid (CHyA) scaffolds were fabri-
cated as previously described.31 Briefly, collagen type I 
derived from bovine Achilles tendon (Collagen Matrix, 
Oakland, NJ, USA) and hyaluronic acid (HyA) sodium salt 
derived from streptococcus equi (Sigma-Aldrich, Arklow, 
Ireland) were blended with a 0.5 M acetic acid (Sigma) 
solution to give suspensions with final concentrations of 
0.5% (w/v) collagen and 0.05% (w/v) HyA. Subsequently, 
the suspensions were freeze-dried (Virtis Genesis 25EL; 
Biopharma, Winchester, UK) to a final freezing tempera-
ture of −10°C with an additional annealing step prior to 
drying. The resultant scaffolds were then crosslinked using 
dehydrothermal treatment (DHT) under vacuum of 
50 mTorr and a temperature of 105°C in a vacuum oven 
(VacuCell; MMM, Germany) for a duration of 24 h.
NCC isolation and culture
Human NCCs were isolated and cultured as previously 
described.26 Briefly, cartilage fragments from nasoseptal 
were obtained from three donors (n = 3) that underwent 
aesthetic surgery procedures, with informed consent and 
with the approval of the Research Ethics Committee of the 
Clementino Fraga Filho University Hospital, Federal 
University of Rio de Janeiro, Brazil (766/09). Fragments 
were rapidly incubated with collagenase IA (Sigma). Cells 
were harvested by centrifugation and cultured in tissue 
culture flasks with Iscove’s Modified Dulbecco’s Medium 
(IMDM; Sigma Chemical Co.) containing 10% fetal 
bovine serum (FBS; LGC), 100 U/mL penicillin, and 
100 µg/mL streptomycin. Cultures were maintained at 
37°C in a humid atmosphere with 5% CO2, and the medium 
was changed twice a week until cell monolayer reached 
80%–90% confluence. By this level, cells were harvested 
with 0.78 mM ethylenediaminetetraacetic acid (EDTA; 
Gibco BRL, Rockville, MD, USA) and 0.125% trypsin 
(Gibco) and re-seeded at a density of 104 cells/cm2. 
Dissociation with trypsin followed by re-seeding for cell 
expansion was denominated “passage.” Time elapsed on 
each passage was about 1 week. Freshly isolated cells, that 
is, isolated from fragments but not underwent trypsin 
harvesting yet, were considered to be on passage 0. Until 
passage 1, all cells were cultured with 10% FBS. For three-
dimensional (3D) culture, NCCs in third and fifth passages 
were transferred to pellet culture system (n = 3, for each 
condition).32 For third passage pellets, cells were cultured 
in passage 2 in 10% FBS (control condition), 2.5% PRPr 
or 10% PRPr. For fifth passage pellets, cells were cultured 
in passages 2, 3, and 4 in 10% FBS (control condition), 
2.5% PRPr, or 10% PRPr. In another experiment, cells 
were cultured in 10% FBS until passage 3 and on passage 
4 the medium was changed to 2.5% PRPr or 10% PRPr. 
The PRPr used in these experiments was pooled from four 
different donors. For pellet assembly, cells were harvested 
and centrifuged at 300g for 10 min into 15-mL tubes 
(Corning) at a concentration of 2 × 105 cells/tube. Media 
was replaced twice a week, while the pellets remained 
intact. Chondrogenic control media was composed of 
IMDM (Gibco) supplemented with 1 µM insulin (Sigma), 
8 × 10−8 M transferrin (Sigma), 2 × 10−8 M bovine serum 
albumin (Sigma), and 2.5 × 10−4 M ascorbic acid (Sigma). 
For the chondrogenic inductor medium, 10 ng/mL TGF-β2 
(R&D Systems, MN) was added to the chondrogenic con-
trol medium. In some experiments, IMDM supplemented 
with 10% FBS (control condition), 1% PRPr, 2.5% PRPr, 
or 10% PRPr were directly used to culture pellets. After 21 
and 35 days, cultures were fixed in 4% paraformaldehyde 
and embedded in paraffin for histological analysis. The 
culture conditions for NCCs are summarized in a table of 
culture conditions (Table 1).
MSC isolation and culture
Human MSCs (hMSCs) were commercially acquired (PT-
2501; Lonza, Switzerland). Cells were expanded in culture 
using hMSC growth medium consisting of low-glucose 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich) supplemented with 1% penicillin/streptomycin 
(Sigma-Aldrich) and 10% FBS and maintained in a tissue 
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culture incubator at 37°C and 5% CO2. Cells were detached 
from culture flasks using trypsin EDTA (Sigma-Aldrich). 
Subsequently, cells were counted and resuspended at a cell 
density of 10 × 106 cells/mL of medium. For 3D culture, 
9.5-mm diameter, 4-mm height scaffolds were pre-
hydrated in phosphate buffered saline (PBS) for 15 min at 
room temperature. The excess PBS was removed from the 
scaffolds, which were then placed onto 24-well suspension 
plates (Sarstedt, Drinagh, Ireland). A total of 0.5 × 106 cells 
were seeded onto each scaffold (0.25 × 106 cells on each 
side of the scaffold). The scaffolds were subsequently incu-
bated for 15 min before addition of medium. The medium 
was changed every 3 days from the scaffolds, and the study 
was carried out for 14 days. The medium was supplemented 
with either PRPr alone (2.5% or 10%) or a combination of 
PRPr (2.5% or 10%) and chondrogenic factors or a combi-
nation of 10% FBS and chondrogenic factors (control con-
dition). In one condition, cells were previously expanded 
on 2.5% PRPr supplemented hMSC growth medium in 
substitution to 10% FBS prior to seeding onto the scaffolds. 
The chondrogenic factors were 20 ng/mL human TGF-β3 
(Prospec, Rehovot, Israel), 50 µg/mL ascorbic acid (Sigma-
Aldrich), 40 µg/mL proline (Sigma-Aldrich), 100 nM dexa-
methasone (Sigma-Aldrich), 1× ITS (Insulin, Transferrin, 
Selenium) (BD Biosciences, Oxford, UK), and 0.11 mg/mL 
sodium pyruvate (Sigma-Aldrich). The culture medium 
supplemented with these chondrogenic factors was termed 
as chondrogenic medium (CM). The PRPr used in these 
experiments was pooled from four different donors. After 
14 days, samples were separated for gene expression analy-
sis (n = 3, for each condition), sulfated glycosaminoglycan 
(sGAG) quantification (n = 3, for each condition), and com-
pressive modulus evaluation (n = 3, for each condition). 
The culture conditions for MSCs are summarized in a 
table of culture conditions (Table 1).
Cell proliferation assay
Cells were seeded in 96-well plates in quadruplicates at 
1.2 × 104 cells/cm2. Cells were cultured for up to 7 days in 
IMDM (Gibco) supplemented with 10% FBS (control con-
dition) or PRPr in different concentrations (from 1% to 
10%). Medium was not changed until the end of treatment. 
For this experiment, three PRP samples were used as well 
as a mix of those samples in equal parts for each cell type. 
Neutral red uptake assay was performed to evaluate cells 
viability, due to its higher economic advantages and sensi-
bility than other cytotoxicity tests.33 Briefly, 0.005% neu-
tral red (Sigma) solution was incubated for 3 h. A solution 
containing 50% ethanol, 1% acetic acid, and 49% water 
was added to elute the red staining, and absorbance was 
measured at 490 nm (Spectramax M5; Molecular Devices, 
Sunnyvale, CA, USA). Since the number of cells seeded 
was similar in every condition, the increase in the number 
of viable cells over time indicates cell proliferation.
Histology
Samples were fixed in 10% formalin for 1 h and using a 
Histokinette tissue processor (Leica TP1050), were dehy-
drated and paraffin wax embedded. Blocks of wax embed-
ded samples were serially sectioned using a microtoming 
Table 1. Table of culture conditions.
Passage 2 Passage 3 Passage 4 Passage 5 Passage 6 Passage 7 (in scaffold) Condition
NCCs 10% FBS Pellet X X X X Passage 2 in 10% FBS
2.5% PRPr X X X X Passage 2 in 2.5% PRPr
10% PRPr X X X X Passage 2 in 10% PRPr
10% FBS Pellet X X Passages 2 to 4 in 10% FBS
2.5% PRPr X X Passages 2 to 4 in 2.5% PRPr
10% PRPr X X Passages 2 to 4 in 10% PRPr
10% FBS 2.5% PRPr X X Passage 4 in 2.5% PRPr
10% FBS 10% PRPr X X Passage 4 in 10% PRPr
MSCs 10% FBS 2.5% PRPr 2.5% PRPr
10% FBS 10% PRPr 10% PRPr
10% FBS CM + 2.5% PRPr CM + 2.5% PRPr
10% FBS CM + 10% PRPr CM + 10% PRPr
10% FBS 2.5% PRPr CM + 10% FBS CM + 10% FBS_PRPr exp
10% FBS CM + 10% FBS CM + 10% FBS_FBS exp
NCCs: nasoseptal chondrogenic cells; MSCs: mesenchymal stromal cells; FBS: fetal bovine serum; PRPr: platelet-rich plasma releasate; CM: chondro-
genic medium.
All culture conditions summarized for NCCs and MSCs. Passages where no culture or experiment was performed on the determined condition are 
marked with an X symbol. Light green shade corresponds to 10% FBS treatment, yellow to 2.5% PRPr, light blue to 10% PRPr, orange to CM + 2.5% 
PRPr, dark blue to CM + 10% PRPr, and dark green to CM + 10% FBS.
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machine (Leica RM2255) which sliced the samples 
at 5-µm-thick sections. The sections were successively 
mounted on polylysine-coated glass slides (Fisher-
Scientific, Ireland). The slides were deparaffinized and 
hydrated before they were stained with alcian blue 1% at 
pH 1.0 (w/v, pH 1.0) (Sigma), to demonstrate sGAG depo-
sition. Then, slides were counterstained with neutral red 
0.5% (w/v) (Sigma). The sections were subsequently 
dehydrated and mounted with cover slides using distyrene–
plasticizer– xylene (DPX). Images were obtained with a 
microscope (Leica DMI 6000 B) equipped with a digital 
camera (Leica DFC 500). Alcian blue pH 1.0 staining is 
routinely used on in vitro chondrogenic induction proto-
cols.34–39 At low pH, all carboxylic and phosphoric acid 
groups are neutralized, and at a high ionic strength, this 
tetravalent cation strongly binds to some negatively charged 
polymers, as glycosaminoglycans (GAGs), but not others, 
as nucleic acids.40 The analyses of stained sections focused 
on the determination of the presence of hyaline cartilage 
characteristics, as an ECM rich in sGAG, where a more 
intense blue-colored ECM is an indicator of higher sGAG 
deposition, cells with a round chondrocyte morphology, 
and an outer fibroblastic perichondrium-like zone.
Pellet area measurement
After samples were fixed, but before dehydration for par-
affin embedment, images were obtained with a microscope 
(Leica DMI 6000 B) equipped with a digital camera (Leica 
DFC 500). Low magnification was used in order for the 
entire sample to be captured. The measurement of the pel-
let area in those images was then performed using the Fiji 
Is Just ImageJ 1.49a software.41
Quantitative polymerase chain reaction
For gene expression analysis, total RNA was isolated using 
an RNeasy kit (Qiagen, Crawley, UK) as previously 
described (Duffy et al., 2011). A total of 200 ng of total RNA 
was reverse transcribed to complementary DNA (cDNA) 
using a QuantiTect reverse transcription kit (Qiagen) on an 
authorized thermal cycler (Mastercycler Personal; Eppendorf, 
Stevenage, UK). Real-time polymerase chain reactions 
(PCRs) were run on 7500 real-time PCR System (Applied 
Biosystems, Paisley, UK) using a QuantiTect SYBR Green 
PCR Kit (Qiagen). The relative expression of messenger RNA 
(mRNA) was calculated by delta–delta Ct (ΔΔCt) method, 
where the fold increase of gene expression was 2−(ΔΔCt).42 
Target mRNA analyzed were SOX9, COL2A1, ACAN, and 
COL10A1, with GAPDH used as a housekeeping gene.
sGAG quantification
For sGAG quantification, scaffolds were digested in papain 
enzyme solution containing 0.5 M EDTA, cysteine-HCl, 
and 1 mg/mL papain enzyme (Carica papaya; Sigma-
Aldrich), and sGAG quantification was performed with 
Blyscan™ (Biocolor Life Science Assays, Carrickfergus, 
UK) according to the manufacturer’s instructions. Readings 
were taken from a photometric plate reader (Wallac 1420 
Victor2 D; Perkin Elmer, MA, Waltham, USA) at 656 nm.
Mechanical testing: compressive modulus analysis
For compressive modulus evaluation, unconfined compres-
sive testing was carried out on seeded scaffold samples 
incubated in PBS using a mechanical testing machine 
(Zwick-Roell, Rehovot and Ulm, Germany). Briefly, the 
mechanical testing machine (Z050; Zwick-Roell, 
Germany) was fitted with a 5-N load cell and tests were 
conducted at a strain rate of 10% per minute with each 
sample being tested three times. Stress was calculated 
from scaffold surface area and applied force, while strain 
was calculated from displacement of the scaffolds in rela-
tion to the original thickness. The compressive modulus 
was defined based on the slope of a linear fit to the stress–
strain curve over 2%–5% strain.
Statistical analysis
Results are expressed as mean ± standard deviation for at 
least three replicates. One-way nonparametric analysis of 
variance followed by the Tukey post-hoc test (to compare 
all pairs in group) was assessed to verify statistical signifi-
cance; p < 0.05 was considered statistically significant. 
Statistical analysis was performed using Prism 5.00 soft-
ware (GraphPad Software Inc., San Diego, CA, USA).
Results
PRPr formulation
Platelet concentration may differ according to the method 
used to obtain PRP. Herein, we have tested two different 
centrifugation methods to concentrate platelets and no 
statistical difference was observed between them. Out of 
13 patients, platelet numbers varied from 0.92 to 
3.76 × 106 µL−1. These concentrations were further con-
sidered to prepare PRPr.
PRPr effect on NCCs
NCC proliferation. To evaluate PRPr activity on cell 
expansion in vitro, NCCs were cultured in 1%, 2.5%, 
5%, and 10% of PRPr supplemented culture medium 
(Figure 1(a)). Cells cultured in 2.5% of PRPr presented 
a similar proliferation rate compared to 10% FBS and 
maintained similar phenotype (Figure 1(b) and (c)). 
However, the proliferation rate increased when cells 
were cultured in 5% and 10% of PRPr, and NCCs 
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changed to small polygonal-shaped cells when cultured 
in 10% PRPr (Figure 1(d)). After these observations, 
further experiments were achieved only with 2.5% and 
10% PRPr. All experiments were achieved using 10% 
FBS as reference.
PRPr onto NCC pellets. To evaluate PRPr capacity to induce 
chondrogenic differentiation, third passage NCCs were 
cultured in 3D pellet system for 21 days in different con-
centrations of PRPr, as described. PRPr direct administra-
tion onto the pellet culture failed to promote full 
chondrogenic differentiation of NCCs in vitro (Figure 
1(e)–(g)). However, pellets cultured in 10% PRPr (Figure 
1(g)) presented more intense staining for synthesized 
ECM, as well as some round-shaped chondrocyte-like 
cells. Of note, all PRPr-treated pellets presented an outer 
layer of cells circulating the pellets, in a perichondrium-
like structure.
PRPr pre-treatment on low-passage NCCs. Hereafter, 
NCCs were cultured in two-dimensions (2D) in 2.5% 
PRPr, 10% PRPr, and 10% FBS in passage 2 and then 
transferred to 3D pellet culture in passage 3 with or 
without TGF-β, to evaluate cartilage-like formation 
(Figure 2). Similar cartilage-like pellets were formed in 
all three conditions. However, it can be noticed that, 
after 21 days of culture, 2.5% PRPr treatment resulted in 
pellets that best resemble a hyaline cartilage–like struc-
ture, with intense ECM staining and more cells with 
chondrocyte-like morphology. Although no statistical 
significance was observed, PRPr-treated pellets, in spe-
cial 10% PRPr, were also larger than 10% FBS–treated 
pellets (Figure 4(a)). Only after 35 days, 10% FBS treat-
ment resulted in pellets with intense ECM staining, high 
number of cells with chondrocyte morphology and as 
large as PRPr-treated ones (Figures 2 and 4(b)).
PRPr pre-treatment on high-passage NCCs. As observed 
(Figure 2), NCCs can originate a cartilage-like pellet up to 
the third passage when pre-treated with FBS or PRPr. 
However, higher passage expansion with FBS is associ-
ated with chondrocyte dedifferentiation and loss of chon-
drogenic capacity.7,8 To test whether a similar process 
would happen with NCCs and how PRPr could affect it, 
NCCs were expanded in 2D cultures from passage 2 to 
passage 4 in the presence of 2.5% and 10% PRPr and 
then changed to 3D pellet cultures on the fifth passage. 
Expansion in 10% FBS was used as control (Figure 3). 
Expansion in 10% FBS clearly hampered NCCs cartilage-
like pellet formation. A fibrous inner spot with poor carti-
lage-like histological characteristics was observed. Only 
in a few spots of the pellet, cells from the periphery dem-
onstrated mild chondrogenic differentiation. Conversely, 
PRPr pre-treatment resulted in pellets with intense sGAG 
production and mostly cells with typical chondrocyte 
morphology. Moreover, both 2.5% and 10% PRPr pre-
treated pellets were significantly larger than 10% FBS 
pre-treated pellets, all cultured under TGF-β induction, 
after 21 days of culture. No difference was observed 
between the two concentrations of PRPr whatsoever (Fig-
ure 4(c)). After 35 days of culture under TGF-β induction, 
2.5% PRPr pre-treated pellets were again larger than the 
other groups, although with no statistical significance 
(Figure 4(d)).
Figure 1. Direct use of PRPr on NCCs expansion and chondrogenic differentiation. (a) NCCs viability curves in the presence of 
PRPr samples in different concentrations compared to 10% FBS. All values regard to absorbance normalized to 10% FBS neutral red 
assay absorbance on day 7. The data are presented as a mean and the error bars correspond to standard deviation (SD); (b) 10% 
FBS–, (c) 2.5% PRPr–, and (d) 10% PRPr–treated cells in monolayer culture in passage 2. Pellets of cells in passage 3 in the presence 
of (e) 10% FBS, (f) 2.5% PRPr, and (g) 10% PRPr for 21 days. Sulfated GAGs evidenced by alcian blue pH1.0 staining (blue) and cells 
nuclei by neutral red (red). Outer layer of fibroblastic cells, which regards a perichondrium layer (p). Scale bars: 50 µm.
PRPr: platelet-rich plasma releasate; NCCs: nasoseptal chondrogenic cells; FBS: fetal bovine serum; GAGs: glycosaminoglycans.
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PRPr and NCC chondrogenic recommitment. The data pre-
sented above indicate that PRPr could prevent NCCs loss 
of chondrogenic potential after in vitro expansion, at least 
up to the fifth passage, even at low concentrations. To test 
whether the releasate would stimulate phenotype “recov-
ery” after NCCs expansion, fourth-passage NCCs were 
cultured in the presence of PRPr only one passage prior to 
3D pellet culture. Our results showed that cells recommit-
ted and differentiated toward the chondrogenic lineage 
when pre-treated with PRPr (Figure 3). Pellets cultured in 
these conditions showed evidence of chondrogenesis with 
more intensively stained and a large area of synthesized 
sGAG-rich matrix, and more clear round chondrocyte-like 
cells, than those that were cultured in 10% FBS until pas-
sage 4 (Figure 3). Although those remarkable chondro-
genic histological characteristics could be found both in 
2.5% PRPr and 10% PRPr pre-treated on passage 4 pellets, 
the 2.5% PRPr pre-treated ones were significantly larger 
than 10% FBS pre-treated pellets from passage 2 to pas-
sage 4 under TGF-β induction and after 21 days of culture 
(Figure 4(c)).
PRPr effect on MSCs
PRPr effect on MSC proliferation and chondrogenic gene 
expression. As compared to NCCs, 2.5% PRPr also pre-
sented the most similar effects on MSCs proliferation com-
pared to 10% FBS (Figure 5(a)). To verify their chondrogenic 
differentiation, passage 7 MSCs were seeded on CHyA 
scaffolds for 14 days in the presence of 2.5% and 10% PRPr 
alone or in CM supplemented with 2.5% PRPr and 10% 
PRPr. CM supplemented with 10% FBS was used as refer-
ence. FBS group was divided into two subgroups, as MSCs 
were pre-treated on passage 6 with 10% FBS or 2.5% PRPr. 
A higher SOX9 expression was observed on PRPr-based 
conditions (Figure 5(b)), as well as COL2A1 (Figure 5(c)), 
with the exception of CM supplemented with 10% PRPr. 
Low concentrations of PRPr led to the highest ACAN 
expression (Figure 5(d)). CM supplemented with 2.5% 
PRPr presented COL10A1 expression statistically similar 
to the control group, which was the CM supplemented with 
10% FBS, with cells expanded in 10% FBS (Figure 5(e)).
PRPr effect on MSC sGAG production and CHyA seeded bio-
mechanical properties. To verify whether higher chondro-
genic gene expression on PRPr groups resulted in higher 
biochemical and biomechanical improvement, sGAG pro-
duction and compressive modulus evaluation were per-
formed. Biochemical analyses evidenced that higher 
sGAG production was observed in the CM supplemented 
with 2.5% PRPr. On the other hand, other conditions 
showed lower amount of sGAG production than the con-
trol group (Figure 6(a)). The groups in which PRPr 
replaced FBS in the CM presented higher mechanical 
properties than those maintained in FBS. In contrast, 
PRPr alone, that is, without the addition of CM, was not 
Figure 2. Effect of PRPr pre-treatment on passage 3 pellet culture system. Pellets of cells that were pre-treated in 2D in passage 2 in 
the presence of 10% FBS, 2.5% PRPr, and 10% PRPr for 21 or 35 days. Pellets were cultured in serum-free medium with (w/) or without 
(w/o) TGF-β. Sulfated GAGs evidenced by alcian blue pH 1.0 staining (blue) and cells nuclei by neutral red (red). Scale bars: 100 µm.
PRPr: platelet-rich plasma releasate; FBS: fetal bovine serum; GAGs: glycosaminoglycans.
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enough to induce higher levels of compressive modulus, 
with values remaining even lower than in CM groups sup-
plemented with 10% FBS (Figure 6(b)).
Discussion
In this study, using two different cell culture models, we 
observed that PRPr efficiently modulated cells prolifera-
tion, chondrogenic commitment, and differentiation, in a 
concentration-dependent manner.
PRP concentration apparently has a great impact on 
clinical outcomes. For bone regeneration, platelet con-
centration in PRP has an optimal limited concentration 
range, approximately 106 µL−1 (five times higher than the 
200 × 103 µL−1 average platelet concentration in periph-
eral blood). Lower concentrations present suboptimal 
effects; on the contrary, higher platelet concentration 
seems to inhibit bone growth.43 When we cultured cells 
in 2.5% PRPr, the releasate induced cell proliferation 
similarly to 10% FBS, both NCCs and MSCs. Other stud-
ies pointed PRP concentration around 1% in cells culture 
medium to be similar to the control group regarding cell 
proliferation.44,45 On the other hand, human platelet 
lysate used to expand adipose-derived mesenchymal pro-
genitor cells at the concentration of 2.5% has been previ-
ously shown to maintain cells phenotype and ability to 
differentiate toward adipogenic lineage.46 Our data also 
showed that no significant increase in cell proliferation 
Figure 3. Effect of PRP pre-treatment on passage 5 pellet culture system. Pellets of cells which were pre-treated in 2D from 
passage 2 to passage 4 in the presence of 10% FBS, 2.5% PRPr, and 10% PRPr, or until passage 3 in 10% FBS and only in passage 4 in 
the presence of 2.5% PRPr and 10% PRPr, for 21 or 35 days. Pellets were cultured in serum-free medium with (w/) or without (w/o) 
TGF-β. Sulfated GAGs evidenced by alcian blue pH 1.0 staining (blue) and cells nuclei by neutral red (red). Inner fibrous layers of 
10% FBS pre-treated pellets are highlighted in ellipses. Scale bars: 100 µm.
PRP: platelet-rich plasma; FBS: fetal bovine serum; PRPr: platelet-rich plasma releasate; GAGs: glycosaminoglycans.
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was induced when PRPr concentration was changed to 
5% and 10%, probably due to the reach of an optimal 
induction of proliferation already at the concentration of 
5%. This phenomenon has been reported previously by 
another group using articular chondrocytes.47 For menis-
cus cell culture, no difference in proliferation results has 
been reported when increasing from 10% to 20% PRP.48 
For fibroblasts, the plasma rich in growth factors (PRGF) 
had similar effects on tendon and skin-derived, while a 
dose-dependent effect was seen on synovium-derived, 
according to platelet concentration.49
NCCs changed to possess a small polygonal-shape 
when cultured in higher concentrations of PRPr, com-
pared to the fibroblast-like morphology in lower concen-
trations of PRPr and the FBS. This change in cell 
morphology may be correlated to their proliferation rate, 
where 10% FBS and 2.5% PRPr are similar and 10% 
PRPr is higher than both. Probably, the lower proliferation 
rate allows cells to elongate and acquire a fusiform fibro-
blast-like morphology in culture, which does not occur 
when cells proliferate more rapidly. To assess the effects 
of PRPr on cells chondrogenic commitment, a pellet cul-
ture system was chosen for NCCs to readily verify through 
histological analysis this already committed cell popula-
tion chondrogenic capacity. On the other hand, a scaffold 
system was chosen for MSCs, as it represents a model for 
future tissue engineering therapy approach with undiffer-
entiated cells extensively used for this purpose. In this 
case, gene expression and biochemical and biomechanical 
analyses were done to evaluate chondrogenic differentia-
tion. When PRPr or FBS were directly incorporated within 
the NCCs pellets cultures, it was not possible to achieve a 
chondrogenic differentiation as expected. Similar to our 
findings, synovium-derived MSC pellets cultured directly 
in the presence of PRP did not present chondrogenic dif-
ferentiation, which was only successfully achieved in the 
presence of a CM supplemented with BMP-2 and TGF-
β1.50 In fact, pellet culture system is usually performed 
under serum-free conditions.32,51 Because of this, instead 
of adding PRPr directly to pellets, the cells were expanded 
in the presence of PRPr and subsequently cultured in 3D 
pellets at the following passage. This approach has previ-
ously been utilized for canine chondrocytes, by priming 
cells with TGF-β1, basic fibroblast growth factor (bFGF), 
and PDGF-BB, which are also present in PRP.30 In that 
study, although cell priming during monolayer expansion 
led to a dedifferentiated phenotype, later pellet culture 
demonstrated their higher chondrogenic feature compared 
to control group, where those growth factors were not 
present.52
Figure 4. Quantification of NCCs pellet areas. Areas (mm2) of (a) passage 3 pellets cultured for 21 days, (b) passage 3 pellets 
cultured for 35 days, (c) passage 5 pellets cultured for 21 days, (d) and passage 5 pellets cultured for 35 days, in medium without 
(w/o) or with (w/) TGF-β. Asterisks represent statistical significance compared to 10% FBS pre-treated pellets (p < 0.05).
NCCs: nasoseptal chondrogenic cells; FBS: fetal bovine serum.
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At low passage, 2.5% PRPr was enough to further 
induce NCCs chondrogenic differentiation after a shorter 
period than cells expanded in 10% FBS. This could be 
interpreted as the ability of cells to more promptly respond 
to chondrogenic induction when treated with a low con-
centration of PRPr compared to 10% FBS. At high pas-
sage, cells which have been cultured on PRPr showed 
pellets with a more similar morphology to hyaline carti-
lage than those from cells previously cultured on 10% 
FBS. In vitro culture can alter cell physiology and lead to 
a loss of chondrogenic capacity,11 and PRPr was able to 
prevent and reverse it. Taken together with the pellet area 
measurement results, it is possible to conclude that the use 
of PRPr at the concentration of 2.5% was enough to main-
tain NCCs chondrogenic commitment and to induce its 
recommitment when lost after FBS expansion. Although 
other in vitro studies point PRP as a dedifferentiation/
fibrogenic inducer,44,53 our results are in accordance with 
studies that demonstrate PRP in vitro chondrogenic induc-
tion on chondrocytes.47,54
PRPr supported SOX9, COL2A1, and ACAN gene expres-
sion, markers of chondrogenic lineage, and COL10A1  
expression, marker of chondrocytes hypertrophy on MSCs 
seeded on CHyA scaffolds. However, the use of CM sup-
plemented with 2.5% PRPr showed the most remarkable 
characteristics regarding chondrogenic induction, as well 
as basal levels of COL10A1 expression. Interestingly, CM 
supplemented with 10% PRPr did not show increase in 
COL2A1, as well as presented high levels of COL10A1, 
which could be an indicator of hypertrophy. However, fur-
ther evaluation to support the hypothesis of a higher amount 
of PRPr being related to MSCs hypertrophy is still needed. 
Although PRPr alone was sufficient to increase some chon-
drogenic genes, probably due to post-transcription factors, 
it was not able to induce greater sGAG production nor bio-
mechanical properties, only achieved when CM was also 
present. The highest sGAG content was observed in the 
samples cultured with CM supplemented with 2.5% PRPr, 
while in CM supplemented with 10% PRPr it was lower 
than the control group. The highest compressive modulus 
was achieved in CM supplemented with PRPr groups, fol-
lowed by CM supplemented with FBS groups and finally 
by PRPr alone groups. Interestingly, the compressive mod-
ulus did not present significant difference between 2.5% 
and 10% PRPr alone or in the presence of CM. In addition, 
although CM supplemented with 10% FBS had smaller 
Figure 5. PRPr effects on MSC expansion and gene expression. (a) MSC viability curves in the presence of PRPr samples 
in different concentrations compared to 10% FBS. All values regard to absorbance normalized to 10% FBS neutral red assay 
absorbance on day 7. The data are presented as a mean and the error bars correspond to standard deviation (SD). MSCs were 
cultured on CHyA scaffolds supplemented with 2.5% PRPr, 10% PRPr, chondrogenic medium with 2.5% PRPr (CM + 2.5% PRPr), 
chondrogenic medium with 10% PRPr (CM + 10% PRPr), chondrogenic medium with 10% FBS in cells expanded in 2.5% PRPr 
(CM + 10% FBS_PRPr exp), and chondrogenic medium with 10% FBS in cells expanded in 10% FBS (CM + 10% FBS_FBS exp), which 
was considered the control condition, and by which the delta Ct results were normalized. (b) SOX9, (c) COL2A1, (d) ACAN, and  
(e) COL10A1 were analyzed. The results were normalized to the control condition and expressed as relative expression. For  
(e), similar symbols between groups represent statistic similarity among them (p > 0.05). The data are presented as a mean, and the 
error bars correspond to SD.
PRPr: platelet-rich plasma releasate; MSC: mesenchymal stromal cell; FBS: fetal bovine serum; CHyA: collagen-hyaluronic acid; CM: chondrogenic 
medium.
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effect on chondrogenic gene expression, the compressive 
modulus of these scaffolds was higher than of the ones 
treated with PRPr alone. These could be explained by the 
fact that the increase in compressive modulus is correlated 
to various factors. For example, sGAG content has a mod-
est correlation to compressive modulus on tissue-engineered 
constructs. Other ECM components and the remodeling 
of the construct throughout culture also affect its mechan-
ical properties.55 The pre-expansion of MSCs on the pas-
sage prior to scaffold culture, in a similar way that it was 
investigated for NCCs, was not possible to induce a 
higher chondrogenic capacity than those pre-treated with 
10% FBS.
Taken together, these results point that the presence of 
CM for MSC chondrogenesis in this model is highly 
important. Moreover, the substitution of the traditionally 
used 10% FBS supplementation in the CM by 2.5% PRPr 
showed to be an interesting strategy, as evidenced by gene 
expression, sGAG synthesis, and compressive modulus 
measurement, while by 10% PRPr could represent hyper-
trophy. A low concentration of PRPr enhanced the capacity 
of MSCs to differentiate to the chondrogenic lineage com-
pared to 10% FBS, and although in a different model, in a 
similar way of the NCCs findings. Nevertheless, as in an 
undifferentiated state, a higher PRPr concentration could 
induce MSCs to a different phenotype. It has been shown 
that when PRP clot is added directly to culture, it presented 
an inhibition toward chondrogenesis both for chondro-
cytes and MSCs.56 Probably, the differences in PRP con-
centration in medium could explain this opposing result 
compared to our study. On the other hand, it has been 
recently reviewed that PRP showed to enhance, or at least 
did not hinder, MSCs chondrogenic phenotype in vitro.57 
Also, the role of PRP as a valid augmentation for cartilage 
scaffolds has been investigated in a number of preclinical 
studies with the majority confirming promising results for 
scaffolds combined with PRP.17
Finally, the different effects of low and high concentra-
tions of PRPr on cells chondrogenesis can also be discussed 
under the light of cell proliferation. It has been shown that 
between day 0 and day 7 of pellet culture system, the num-
ber of MSCs is increased in 30%, thus indicating cell pro-
liferation. From day 7, the number of cells decreases, and 
collagens, proteoglycans, and other matrix components’ 
gene expression is generally upregulated.58 Proliferation is 
indeed a requirement for in vitro chondrogenesis of MSCs. 
Treatment with mitomycin C, which blocks proliferation, 
hampered MSC chondrogenic differentiation. On the other 
Figure 6. Biochemical and biomechanical effects of PRP on CHyA seeded scaffolds following 14 days of culture. sGAG synthesis 
was evaluated by biochemical analysis and the values were normalized by DNA content. Cultures were supplemented with 2.5% 
PRPr, 10% PRPr, chondrogenic medium with 2.5% PRPr (CM + 2.5% PRPr), chondrogenic medium with 10% PRPr (CM + 10% PRPr), 
chondrogenic medium with 10% FBS in cells expanded in 2.5% PRPr (CM + 10% FBS_PRP exp), and chondrogenic medium with 
10% FBS in cells expanded in 10% FBS (CM + 10% FBS_FBS exp), which was considered the control condition, by which all results 
were normalized. (a) Asterisks and cross represent p < 0.05 compared to 10% FBS, and similar symbols between groups represent 
statistic similarity among them (p > 0.05). Compressive modulus of CHyA seeded scaffolds. (b) Asterisks and cross represent 
p < 0.05 compared to 10% FBS, and similar symbols between groups represent statistic similarity among them (p > 0.05). The data 
are presented as a mean and the error bars correspond to standard deviation (SD).
PRP: platelet-rich plasma; CHyA: collagen-hyaluronic acid; sGAG: sulfated glycosaminoglycan; PRPr: platelet-rich plasma releasate; CM: chondrogenic 
medium; FBS: fetal bovine serum.
 at ROYAL COLLEGE OF SURGEONS on August 17, 2016tej.sagepub.comDownloaded from 
12 Journal of Tissue Engineering 
hand, little proliferation is observed after 21 days in pellet 
culture system in areas with strong matrix deposition.34 
Those in vitro studies seem to mimic embryonic chondro-
genesis, where cells initially undergo extensive prolifera-
tion, which eventually stops prior to matrix deposition and 
cartilaginous nodules formation.59,60 Thus, the results in 
this work showing greater enhancement of chondrogenic 
phenotype under 2.5% PRPr treatment rather than 10% 
PRPr may be correlated to the more intensive effect on cell 
proliferation by 10% PRPr than 2.5% PRPr.
Conclusion
In the work presented in this article, it was possible to pro-
duce a PRPr capable of eliciting an enhanced chondro-
genic effect in vitro, which when used as a substitute to 
FBS prevented NCCs dedifferentiation as well as pro-
moted their redifferentiation toward the chondrogenic lin-
eage. In the case of MSCs, PRPr induced the expression of 
chondrogenic markers, production of sGAG, and increase 
in biomechanical properties in a scaffold culture system. 
Collectively, we can conclude that PRPr can be used as a 
substitute for FBS for in vitro 2D expansion of chondro-
genic cells, with special regard to its concentration, cell 
type, and passage. Further work is required to confirm 
whether cellular expansion with PRPr will enhance carti-
lage repair in vivo.
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